Drugs / Bemotuzumab
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT07358676 | Feb 2026 → Jan 2027 expected | small cell lung carcinoma | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06975644 | Sep 2025 → Sep 2026 expected | triple-negative breast carcinoma | Zhejiang Provincial People's Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bemotuzumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06975644 ↗ |
| Route | Intravenous | “Bemotuzumab (1200 mg IV, Day 1)” NCT07358676 ↗ |